The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 16.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission of the First Tranche Placing Shares

29 Apr 2024 07:00

RNS Number : 2850M
Renalytix PLC
29 April 2024
 

Renalytix plc

("Renalytix" or the "Company")

 

Admission of the First Tranche Placing Shares

 

LONDON and SALT LAKE CITY - 29 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) confirms that, further to the announcements made on 12 March 2024 and 15 March 2024, the First Resale Registration Statement is expected to become effective later today and accordingly an application has been made to London Stock Exchange plc for the admission to trading of the First Tranche Placing Shares. The First Tranche Placing Shares, being 19,986,031 shares, were issued on 14 March 2024 and will be admitted to trading on AIM on 30 April 2024 at 8am.

 

The First Tranche Placing Shares have been credited as fully paid and rank pari passu in all respects with the Company's existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of such shares after the date of issue.

 

Capitalised terms used but not defined in this announcement have the meanings given to them in the announcement dated 12 March 2024, unless the context provides otherwise.

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

 

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 

Harry Billen

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 

Walbrook PR Limited

Paul McManus / Alice Woodings / Charlotte Edgar

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

Disclosure requirements of the Takeover Code

Under Rule 8.3(a) of the City Code on Takeovers and Mergers ("Takeover Code"), any person who is interested in one per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in one per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUMCCUPCGAQ
Date   Source Headline
28th Sep 20237:00 amRNSRenalytix Reports Full Year Fiscal 2023 Results
25th Sep 20237:00 amRNSNotice of Results
22nd Sep 20237:00 amRNSPayer coverage expansion of KidneyIntelX
7th Sep 20237:00 amRNSAppointment of Chief Business Officer
21st Aug 20237:00 amRNSBusiness Update
3rd Aug 20239:10 amRNSRSU vesting for employees
3rd Aug 20237:00 amRNSFormation of Clinical Advisory Board
21st Jul 20237:00 amRNSVector Pharma Middle East Distribution Agreement
17th Jul 20231:43 pmRNSIssue of Shares - Replacement
17th Jul 20237:00 amRNSIssue of Shares
7th Jul 20237:00 amRNSKidneyIntelX evidence presented at ADA
6th Jul 20235:38 pmRNSGrant of Share Options
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSFDA Approves KidneyIntelX.dkd™
15th Jun 20237:00 amRNSPresentation of Scientific Data
9th Jun 20237:00 amRNSFinancial Results for Q3 of Fiscal Year 2023
8th Jun 20233:30 pmRNSResult of General Meeting
5th Jun 20237:00 amRNSNotice of Q3 Results
25th May 20237:00 amRNSEVERSANA® partnership for KidneyIntelX
22nd May 20237:00 amRNSExpansion of insurance coverage for KidneyIntelX
11th May 20237:00 amRNSNotice of GM and Posting of Circular
19th Apr 20237:00 amRNSReal-World Evidence Shows KidneyIntelX™ Utility
12th Apr 20237:00 amRNSPositive Data Release at NKF Conference
30th Mar 20237:00 amRNSHalf-year Report
27th Mar 202312:50 pmRNSBusiness Update - Replacement
27th Mar 20237:00 amRNSBusiness Update
22nd Mar 20237:00 amRNSNotice of Results
21st Mar 20232:05 pmRNSSecond Price Monitoring Extn
21st Mar 20232:00 pmRNSPrice Monitoring Extension
21st Mar 20237:00 amRNSUpdate on FDA De Novo Authorization Process
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
7th Mar 20237:00 amRNSIssue of Shares
10th Feb 20233:13 pmRNSHolding(s) in Company
10th Feb 20232:01 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSRENX to Participate in the BTIG MedTech Conference
8th Feb 20237:00 amRNSRenalytix announces a c.$20.3m private placement
26th Jan 20237:00 amRNSRenalytix and Partners Awarded $10 Million Grant
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSCompletes Agreement with Veterans Administration
19th Dec 202212:01 pmRNSResult of AGM
1st Dec 20227:00 amRNSClinical utility study data: further highlights
30th Nov 20227:00 amRNSResults for First Quarter of Fiscal Year 2023
29th Nov 20227:00 amRNSPublication of new real world evidence
22nd Nov 20227:00 amRNSNotice of Q1 FY23 Results
10th Nov 20227:00 amRNSPublication of Annual Report 2022 & Notice of AGM
9th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSRENX to Present at Stifel Healthcare Conference
31st Oct 20224:41 pmRNSSecond Price Monitoring Extn
31st Oct 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.